Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Deferred Taxes (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Deferred Taxes over the past 15 years, most recently at $109000.0 for Q4 2024.

  • Quarterly results put Deferred Taxes at $109000.0 for Q4 2024, up 372.5% from a year ago — trailing twelve months through Nov 2024 was $136000.0 (down 66.5% YoY), and the annual figure for FY2024 was $163000.0, down 54.34%.
  • Deferred Taxes for Q4 2024 was $109000.0 at Lifecore Biomedical, Inc. \De\, up from -$100000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for LFCR hit a ceiling of $4.7 million in Q4 2020 and a floor of -$7.7 million in Q1 2021.
  • Median Deferred Taxes over the past 5 years was -$52000.0 (2023), compared with a mean of -$849300.0.
  • Peak annual rise in Deferred Taxes hit 559.73% in 2020, while the deepest fall reached 1774.2% in 2020.
  • Lifecore Biomedical, Inc. \De\'s Deferred Taxes stood at $4.7 million in 2020, then crashed by 160.4% to -$2.8 million in 2021, then skyrocketed by 100.14% to $4000.0 in 2022, then plummeted by 1100.0% to -$40000.0 in 2023, then soared by 372.5% to $109000.0 in 2024.
  • The last three reported values for Deferred Taxes were $109000.0 (Q4 2024), -$100000.0 (Q3 2024), and -$64000.0 (Q2 2024) per Business Quant data.